Javascript must be enabled to continue!
Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial.
View through CrossRef
PURPOSE Diarrhea is a prominent feature of fluorouracil (5FU) gastrointestinal toxicity, especially when 5FU is combined with leucovorin (LV) or interferon (IFN). No treatment for this condition has been well defined, although drugs, such as diphenoxylate or loperamide, generally are used. The efficacy of octreotide in the treatment of 5FU-induced diarrhea recently has been reported. We performed a randomized trial that compared octreotide with loperamide, the drug most commonly used for therapy for this disorder. PATIENTS AND METHODS Forty-one patients with grade 2 (four to six stools per day) or grade 3 (seven to nine stools per day; National Cancer Institute toxicity criteria) diarrhea after chemotherapy with a 5FU-containing regimen for colorectal cancer in 28 cases, gastric cancer in six cases, pancreatic cancer in five cases, and breast cancer in two cases, were entered onto the study. Twenty-one patients received octreotide at a dosage of 0.1 mg subcutaneously twice per day for 3 days, and 20 patients received loperamide 4 mg orally initially and then 2 mg every 6 hours for 3 days. The two arms were comparable for age, sex, and primary tumor. Patients were evaluated for response each treatment day; all patients were assessable. RESULTS Diarrhea resolved in 19 patients in the octreotide arm (one within the first day; four within the second day; and 14 within the third day) versus only three (all after the third day of therapy) in the loperamide arm (P < .005). Median frequency of stools in the 3 days of therapy was four, three, and zero in the octreotide arm and five, five, and five in the loperamide arm. No side effects were observed in both arms. Ten patients on the loperamide arm and only one on the octreotide arm required hospitalization for parenteral replenishment of fluids and electrolytes. CONCLUSION Octreotide seems to be more effective than loperamide in control of diarrhea and elimination of the need for replenishment of fluids and electrolytes.
American Society of Clinical Oncology (ASCO)
Title: Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial.
Description:
PURPOSE Diarrhea is a prominent feature of fluorouracil (5FU) gastrointestinal toxicity, especially when 5FU is combined with leucovorin (LV) or interferon (IFN).
No treatment for this condition has been well defined, although drugs, such as diphenoxylate or loperamide, generally are used.
The efficacy of octreotide in the treatment of 5FU-induced diarrhea recently has been reported.
We performed a randomized trial that compared octreotide with loperamide, the drug most commonly used for therapy for this disorder.
PATIENTS AND METHODS Forty-one patients with grade 2 (four to six stools per day) or grade 3 (seven to nine stools per day; National Cancer Institute toxicity criteria) diarrhea after chemotherapy with a 5FU-containing regimen for colorectal cancer in 28 cases, gastric cancer in six cases, pancreatic cancer in five cases, and breast cancer in two cases, were entered onto the study.
Twenty-one patients received octreotide at a dosage of 0.
1 mg subcutaneously twice per day for 3 days, and 20 patients received loperamide 4 mg orally initially and then 2 mg every 6 hours for 3 days.
The two arms were comparable for age, sex, and primary tumor.
Patients were evaluated for response each treatment day; all patients were assessable.
RESULTS Diarrhea resolved in 19 patients in the octreotide arm (one within the first day; four within the second day; and 14 within the third day) versus only three (all after the third day of therapy) in the loperamide arm (P < .
005).
Median frequency of stools in the 3 days of therapy was four, three, and zero in the octreotide arm and five, five, and five in the loperamide arm.
No side effects were observed in both arms.
Ten patients on the loperamide arm and only one on the octreotide arm required hospitalization for parenteral replenishment of fluids and electrolytes.
CONCLUSION Octreotide seems to be more effective than loperamide in control of diarrhea and elimination of the need for replenishment of fluids and electrolytes.
Related Results
Blunt Chest Trauma and Chylothorax: A Systematic Review
Blunt Chest Trauma and Chylothorax: A Systematic Review
Abstract
Introduction: Although traumatic chylothorax is predominantly associated with penetrating injuries, instances following blunt trauma, as a rare and challenging condition, ...
Somatostatin Analogue Therapy in Functioning Neuroendocrine Gut Tumors
Somatostatin Analogue Therapy in Functioning Neuroendocrine Gut Tumors
The purpose of the workshop was to critically evaluate the use of octreotide in the management of important sugical and gastroenterological conditions. The topics covered included:...
Spanish Breast Cancer Research Group (GEICAM)
Spanish Breast Cancer Research Group (GEICAM)
This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by Spanish Breast Cancer Research Group (GEICAM). Clinical trials...
International Breast Cancer Study Group (IBCSG)
International Breast Cancer Study Group (IBCSG)
This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by International Breast Cancer Study Group (IBCSG). Clinical tria...
Everolimus Plus Octreotide Long-Acting Repeatable in Patients With Colorectal Neuroendocrine Tumors: A Subgroup Analysis of the Phase III RADIANT-2 Study
Everolimus Plus Octreotide Long-Acting Repeatable in Patients With Colorectal Neuroendocrine Tumors: A Subgroup Analysis of the Phase III RADIANT-2 Study
AbstractIntroduction.The incidence of colorectal neuroendocrine tumors (NETs) is increasing, and patients with this disease have particularly poor prognoses. Treatment options are ...
Control of Chemotherapy-Induced Diarrhea with Octreotide
Control of Chemotherapy-Induced Diarrhea with Octreotide
Cisplatin-related diarrhea is a relatively common complication in the clinical management of cancer patients and until now no treatment for this condition has been identified. Octr...
Colchicine Ameliorates 5‐Fluorouracil‐Induced Cardiotoxicity in Rats
Colchicine Ameliorates 5‐Fluorouracil‐Induced Cardiotoxicity in Rats
Background and Objective. 5‐Fluorouracil is one of the most common chemotherapeutic agents used in the treatment of solid tumors. 5‐Fluorouracil‐associated cardiotoxicity is the se...
Inhibition of pancreaticobiliary secretion by loperamide in humans
Inhibition of pancreaticobiliary secretion by loperamide in humans
Loperamide, a peripherally acting opiate receptor agonist with antidiarrheal action, inhibits ileal and colonic motor function. It was determined whether loperamide also affects ga...

